Cytokine traps: Multi-component, high-affinity blockers of cytokine action

Nature Medicine

Volumn 9, Issue 1, 2003, Pages 47-52

  Economides, Aris N ^a   Carpenter, Laura Rocco ^a   Rudge, John S ^a   Wong, Vivien ^a   Koehler Stec, Ellen M ^a   Hartnett, Christopher ^a   Pyles, Erica A ^a   Xu, Xiaobing ^a   Daly, Thomas J ^a   Young, Michael R ^a   Fandl, James P ^a   Lee, Frank ^a   Carver, Scott ^a   McNay, Jennifer ^a   Bailey, Kevin ^a   Ramakanth, Swayampakula ^a   Hutabarat, Renta ^a   Huang, Tammy T ^a   Radziejewski, Czeslaw ^a   Yancopoulos, George D ^b   Stahl, Neil ^a   more..

^a REGENERON PHARMACEUTICALS INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE ANTIBODY; CYTOKINE RECEPTOR; CYTOKINE TRAP; ETANERCEPT; IMMUNOGLOBULIN G; INTERLEUKIN 1; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 6; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CELL PROLIFERATION; CONTROLLED STUDY; DIMERIZATION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOGLOBULIN CONSTANT REGION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DOMAIN; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR AFFINITY; TECHNIQUE;

ANIMALS; ANTIGENS, CD; CELL DIVISION; CELL LINE; CYTOKINE RECEPTOR GP130; CYTOKINES; DIMERIZATION; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; MACACA FASCICULARIS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED STRAINS; PROTEIN BINDING; RANDOM ALLOCATION; RECEPTORS, INTERLEUKIN-6; RECOMBINANT FUSION PROTEINS; TIME FACTORS;

ANIMALIA;

EID: 0037231664     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm811     Document Type: Article

References (37)

1. van Deventer, S.J. Anti-TNF antibody treatment of Crohn's disease. Ann. Rheum. Dis. 58 (Suppl. 1), 1114-1120 (1999).
2. Richard-Miceli, C. & Dougados, M. Tumour necrosis factor-α blockers in rheumatoid arthritis: Review of the clinical experience. Biodrugs 15, 251-259 (2001).
3. Elliott, M.J. et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum. 36, 1681-1690 (1993).
4. Goldenberg, M.M. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin. Ther. 21, 75-87 (1999).
5. Mohler, K.M. et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol. 151, 1548-1561 (1993).
6. Bresnihan, B. et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 41, 2196-2204 (1998).
7. Cohen, S., Hurd, E. & Cush, J. Treatment of interleukin-1 receptor antagonist in combination with methotrexate in rheumatoid arthritis patients. Arthritis Rheum. 42, S273 (1999).
8. Nuki, G., Rozman, B. & Pavelka, K. Interleukin-1 receptor antagonist continues to demonstrate clinical improvement in rheumatoid arthritis. Arthritis Rheum. 40, S224 (1997).
9. Campion, G.V., Lebsack, M.E., Lookabaugh, J., Gordon, G. & Catalano, M. Doserange and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1 Ra Arthritis Study Group. Arthritis Rheum. 39, 1092-1101 (1996).
10. Bresnihan, B. The prospect of treating rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Biodrugs 15, 87-97 (2001).
11. Borish, L.C. et al. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 160, 1816-1823 (1999).
12. Borish, L.C. et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J. Allergy Clin. Immunol. 107, 963-970 (2001).
13. Bataille, R. et al. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 86, 685-691 (1995).
14. Haddad, E. et al. Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial. Blood 97, 1590-1597 (2001).
15. Beck, J.T. et al. Brief report: Alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N. Engl. J. Med. 330, 602-605 (1994).
16. Legouffe, E. et al. Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6. Clin. Exp. Immunol. 98, 323-329 (1994).
17. Carpenter, L.R., Yancopoulos, G.D. & Stahl, N. General mechanisms of cytokine receptor signaling. Adv. Protein Chem. 52, 109-140 (1999).
18. Davis, S. et al. LIFR β and gp130 as heterodimerizing signal transducers of the tripartite CNTF receptor. Science 260, 1805-1808 (1993).
19. Stahl, N. & Yancopoulos, G.D. The alphas, betas, and kinases of cytokine receptor complexes. Cell 74, 587-590 (1993).
20. Taga, T. et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 58, 573-581 (1989).
21. Dinarello, C.A. Biologic basis for interleukin-1 in disease. Blood 87, 2095-2147 (1996).
22. van den Berg, W.B., Joosten, L.A., Helsen, M. & van de Loo, F.A. Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin. Exp. Immunol. 95, 237-243 (1994).
23. Reimers, J. Interleukin-1b induced transient diabetes mellitus in rats. Danish Med. Bull. 45, 157-180 (1998).
24. van den Berg, W.B. Joint inflammation and cartilage destruction may occur uncoupled. Springer Semin. Immunopothol. 20, 149-164 (1998).
25. Joosten, L.A., Helsen, M.M., van de Loo, F.A. & van den Berg, W.B. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF α, anti-IL-1 α/β, and IL-1Ra. Arthritis Rheum. 39, 797-809 (1996).
26. Cieslewicz, G. et al. The late, but not early, asthmatic response is dependent on IL-5 and correlates with eosinophil infiltration. J. Clin. Invest. 104, 301-308 (1999).
27. Wills-Karp, M. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu. Rev. Immunol. 17, 255-281 (1999).
28. Gundel, R. et al. IL-4 induced leucocyte trafficking in cynomolgus monkeys: correlation with expression of adhesion molecules and chemokine generation. Clin. Exp. Allergy 26, 719-729 (1996).
29. Foote, J. & Eisen, H.N. Kinetic and affinity limits on antibodies produced during immune responses. Proc. Natl. Acad. Sci. USA 92, 1254-1256 (1995).
30. Guler, H.-P. et al. A phase 1, single dose escalation study of IL-1 trap in patients with rheumatoid arthritis. Arthritis Rheum. 44, S370 (2001).
31. Wills-Karp, M. et al. Interleukin-13: central mediator of allergic asthma. Science 282, 2258-2261 (1998).
32. Grunig, G. et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 282, 2261-2263 (1998).
33. Coyle, A.J. et al. Interleukin-4 is required for the induction of lung Th2 mucosal immunity. Am. J. Respir. Cell Mol. Biol. 13, 54-59 (1995).
34. Holash, J. et al. VEGF-trap: A VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. USA 99, 11393-11398 (2002).
35. Kim, E.S. et al. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc. Natl. Acad. Sci. USA 99, 11399-11404 (2002).
36. Joosten, L.A., Helsen, M.M. & van den Berg, W.B. Accelerated onset of collagen-induced arthritis by remote inflammation. Clin. Exp. Immunol. 97, 204-211 (1994).
37. Wooley, P.H. et al. The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. Arthritis Rheum. 36, 1305-1314 (1993).